These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21421715)

  • 1. Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250.
    Pryma DA; O'Donoghue JA; Humm JL; Jungbluth AA; Old LJ; Larson SM; Divgi CR
    J Nucl Med; 2011 Apr; 52(4):535-40. PubMed ID: 21421715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.
    Lawrentschuk N; Lee FT; Jones G; Rigopoulos A; Mountain A; O'Keefe G; Papenfuss AT; Bolton DM; Davis ID; Scott AM
    Urol Oncol; 2011; 29(4):411-20. PubMed ID: 19523858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma.
    Cheal SM; Punzalan B; Doran MG; Evans MJ; Osborne JR; Lewis JS; Zanzonico P; Larson SM
    Eur J Nucl Med Mol Imaging; 2014 May; 41(5):985-94. PubMed ID: 24604591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice.
    Stillebroer AB; Franssen GM; Mulders PF; Oyen WJ; van Dongen GA; Laverman P; Oosterwijk E; Boerman OC
    Cancer Biother Radiopharm; 2013 Sep; 28(7):510-5. PubMed ID: 23697926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.
    Stillebroer AB; Boerman OC; Desar IM; Boers-Sonderen MJ; van Herpen CM; Langenhuijsen JF; Smith-Jones PM; Oosterwijk E; Oyen WJ; Mulders PF
    Eur Urol; 2013 Sep; 64(3):478-85. PubMed ID: 22980441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma.
    Muselaers CH; Boerman OC; Oosterwijk E; Langenhuijsen JF; Oyen WJ; Mulders PF
    Eur Urol; 2013 Jun; 63(6):1101-6. PubMed ID: 23453421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma.
    Chrastina A; Závada J; Parkkila S; Kaluz S; Kaluzová M; Rajcáni J; Pastorek J; Pastoreková S
    Int J Cancer; 2003 Jul; 105(6):873-81. PubMed ID: 12767076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial.
    Divgi CR; Pandit-Taskar N; Jungbluth AA; Reuter VE; Gönen M; Ruan S; Pierre C; Nagel A; Pryma DA; Humm J; Larson SM; Old LJ; Russo P
    Lancet Oncol; 2007 Apr; 8(4):304-10. PubMed ID: 17395103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
    Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
    J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary biological evaluation of ¹²⁵I-labeled anti-carbonic anhydrase IX monoclonal antibody in the mice bearing HT-29 tumors.
    Li J; Shi L; Wang C; Zhang X; Jia L; Li X; Zhou W; Qi Y; Zhang L
    Nucl Med Commun; 2011 Dec; 32(12):1190-3. PubMed ID: 21968435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma.
    Davis ID; Liu Z; Saunders W; Lee FT; Spirkoska V; Hopkins W; Smyth FE; Chong G; Papenfuss AT; Chappell B; Poon A; Saunder TH; Hoffman EW; Old LJ; Scott AM
    Cancer Immun; 2007 Aug; 7():14. PubMed ID: 17705350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma.
    Minn I; Koo SM; Lee HS; Brummet M; Rowe SP; Gorin MA; Sysa-Shah P; Lewis WD; Ahn HH; Wang Y; Banerjee SR; Mease RC; Nimmagadda S; Allaf ME; Pomper MG; Yang X
    Oncotarget; 2016 Aug; 7(35):56471-56479. PubMed ID: 27437764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma.
    Davis ID; Wiseman GA; Lee FT; Gansen DN; Hopkins W; Papenfuss AT; Liu Z; Moynihan TJ; Croghan GA; Adjei AA; Hoffman EW; Ingle JN; Old LJ; Scott AM
    Cancer Immun; 2007 Aug; 7():13. PubMed ID: 17705349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET/CT with (124)I-cG250: great potential and some open questions.
    Khandani AH; Rathmell WK; Wallen EM; Ivanovic M
    AJR Am J Roentgenol; 2014 Aug; 203(2):261-2. PubMed ID: 25055257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: experiences from (radio) immunotherapy.
    Brouwers AH; Mulders PF; Oyen WJ
    J Clin Oncol; 2008 Aug; 26(22):3808-9; author reply 3811-2. PubMed ID: 18669472
    [No Abstract]   [Full Text] [Related]  

  • 16. Positron Emission Tomography/Computed Tomography with
    Hekman MCH; Rijpkema M; Aarntzen EH; Mulder SF; Langenhuijsen JF; Oosterwijk E; Boerman OC; Oyen WJG; Mulders PFA
    Eur Urol; 2018 Sep; 74(3):257-260. PubMed ID: 29730017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats.
    Brouwers A; Verel I; Van Eerd J; Visser G; Steffens M; Oosterwijk E; Corstens F; Oyen W; Van Dongen G; Boerman O
    Cancer Biother Radiopharm; 2004 Apr; 19(2):155-63. PubMed ID: 15186595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.
    Brouwers A; Mulders P; Oosterwijk E; Buijs W; Corstens F; Boerman O; Oyen W
    Cancer Biother Radiopharm; 2004 Aug; 19(4):466-77. PubMed ID: 15453961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbonic anhydrase IX expression in clear cell renal cell carcinomas negatively correlates with the proportion of the granular cell component.
    Skapa P; Hyrsl L; Zavada J; Soukup J; Zamecnik J
    J Clin Oncol; 2008 Aug; 26(22):3809-11; author reply 3811-2. PubMed ID: 18669473
    [No Abstract]   [Full Text] [Related]  

  • 20. Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma.
    Zhu W; Li X; Zheng G; Bai C; Ji Z; Zhang H; Xing H; Zhang Y; Huo L
    Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3116-3125. PubMed ID: 37246998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.